Skip to main content
| News

Worg selects Basel Area for European headquarters

03.09.2021

Worg Pharmaceuticals has opted to establish its European headquarters at the site Allschwil of the Switzerland Innovation Park Basel Area. The Chinese biopharmaceutical company develops innovative therapies to treat allergies and autoimmune diseases.

Rainer Henning heads up Worg's European headquarters in Allschwil (img: Worg Pharmaceuticals)

The Switzerland Innovation Park Basel Area will become the hub for the European activities of Worg Pharmaceuticals AG. Founded in 2018, the Chinese biopharmaceutical company is headquartered in Hangzhou and specializes in the development of innovative therapies to treat allergies and autoimmune diseases. The company is led by a management team from China, the USA and Europe.

Business activities in Europe will, according to the company, include both drug discovery and the preclinical and clinical development of the global Worg portfolio. A team of top-class researchers in the fields of chemistry and biology will be formed with the aim of establishing extensive research collaborations with academic institutions across Europe. “Our goal is to bring an IND (Investigational New Drug) candidate onto the market every year”, Worg explains in its company profile.

Worg “carefully examined” a number of possible locations in Europe, with Basel emerging as the front-runner due to the concentration of life sciences companies of all sizes in the region, “which form one of the best clusters in Europe, if not worldwide”. In addition, the large number of elite universities and research institutions in the region will provide the “talent pool” for the positions that are to eventually be filled.

The investment and innovation promotion agency Basel Area Business & Innovation supported Worg in the process of establishing its business in the region with by consulting and providing legal assistance in addition to helping with the property search. Director of Science at Worg, Rainer Henning, also acknowledges these aspects. For 40 years, Henning has worked in the position of CEO at biopharmaceutical companies in addition to holding a leading position in the field of cardiovascular research at Hoechst AG in Frankfurt. He now heads up Worg’s Hub of Business Activities in Europe. “Right from the very start we received incredible support from the management of the Switzerland Innovation Park as well as from experienced law firms and auditors. This enabled our company to get off to a smooth start”, he explains.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Sustainability

KUORI developing biodegradable plastics

The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Cell and gene therapies gain momentum in Basel

Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...

Read More
BLKB expanding support for startups
Basel Area Business & Innovation, Innovation, Invest

BLKB expanding support for startups

BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...

Read More
Combatting the rise of antimicrobial resistance
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Combatting the rise of antimicrobial resistance

Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

AMR Action Fund invests in new antibiotics developed by BioVersys

The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Investors give Resistell 8.5 million Swiss francs

Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...

Read More
1 2 3 60

Do you have a question? We'd like to hear from you.